LEVEL UP data presented at RAD 2024 provide additional insight into the phase 3b/4 trial comparing upadacitinib and dupilumab in atopic dermatitis beyond the primary endpoint.
This late-breaking data featured at RAD 2024 highlights several improvements in patient reported outcomes observed among atopic dermatitis patients, including itch relief.
Nektar Therapeutics (NASDAQ:NKTR) Q1 2024 Earnings Call Transcript insidermonkey.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insidermonkey.com Daily Mail and Mail on Sunday newspapers.
Potential best-in-class antibody shows "remarkable efficacy" in AD europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.
AbbVie shares positive results for Rinvoq in head-to-head atopic dermatitis study pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.